Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

784
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
784
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>ASPSCR1: TFE3</i> Fusion-Positive Epithelioid Angiomyolipoma/PEComa Lacking Melanocytic Markers: A Case Report.

IJU case reports·2026
Same author

Feasibility and Early Outcomes of Single-Port Robot-Assisted Partial Nephrectomy via Supine Low Anterior Access.

Asian journal of endoscopic surgery·2026
Same author

Incidence and Risk Factors for Perioperative Infections After Robot-Assisted Radical Prostatectomy: A Multicenter Study.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate Cancer.

Anticancer research·2026
Same author

Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy.

Japanese journal of clinical oncology·2026
Same author

Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Related Experiment Video

Updated: Feb 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: Current Evidence and Future Directions.

Kiyoshi Takahara1, Akihito Takeuchi1, Masanobu Saruta1

  • 1Department of Urology, Fujita Health University School of Medicine, Toyoake, Japan.

International Journal of Urology : Official Journal of the Japanese Urological Association
|February 15, 2026
PubMed
Summary

Treatment for metastatic castration-sensitive prostate cancer (mCSPC) has advanced beyond androgen deprivation therapy (ADT) to include combination therapies and triplet regimens, improving survival. Optimal patient selection for these advanced treatments remains key for better outcomes in mCSPC.

Keywords:
ARSImCSPCtriplet therapy

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

889
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Related Experiment Videos

Last Updated: Feb 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K
A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

889
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Metastatic castration-sensitive prostate cancer (mCSPC) exhibits significant biological heterogeneity and variable clinical progression.
  • The treatment paradigm for mCSPC has shifted from androgen deprivation therapy (ADT) alone to combination strategies incorporating chemotherapy and novel androgen receptor pathway inhibitors.
  • Landmark trials (CHAARTED, STAMPEDE, LATITUDE) established survival benefits with docetaxel or abiraterone added to ADT, influencing clinical guidelines.

Purpose of the Study:

  • To provide a comprehensive review of current evidence-based treatment strategies for mCSPC.
  • To discuss recent advancements, including triplet therapies and personalized treatment approaches.
  • To explore emerging therapies and future research directions in mCSPC management.

Main Methods:

  • Review of key clinical trials and real-world data on mCSPC treatment.
  • Analysis of outcomes associated with combination therapies and triplet regimens.
  • Discussion of advances in molecular profiling and imaging for patient stratification.

Main Results:

  • Combination therapies (docetaxel/abiraterone + ADT) significantly improve survival in mCSPC.
  • Triplet therapies (ADT + docetaxel + androgen receptor signaling inhibitors) show further outcome improvements.
  • Molecular profiling and advanced imaging facilitate personalized treatment strategies for mCSPC.

Conclusions:

  • The treatment landscape for mCSPC has evolved, with combination and triplet therapies offering survival advantages.
  • Optimal patient selection for intensified treatment regimens is crucial but requires further clarification.
  • Personalized medicine, informed by molecular and imaging data, is essential for improving long-term outcomes in mCSPC.